News
IRD
4.200
+0.48%
0.020
Weekly Report: what happened at IRD last week (1102-1106)?
Weekly Report · 18h ago
Analysts’ Opinions Are Mixed on These NA Stocks: Pan American Silver (PAAS), Opus Genetics (IRD) and Blue Owl Technology Finance Corp. (OTF)
TipRanks · 4d ago
Opus Genetics completes dosing in higher-dose Cohort 2 of BIRD-1 trial
TipRanks · 4d ago
Weekly Report: what happened at IRD last week (1026-1030)?
Weekly Report · 11/02 09:58
Press Release: Opus Genetics Appoints Dr. Andrew Murphy as Chief Scientific Officer and Jamie Lynne Hart as Executive Director, Executive Operations
Dow Jones · 10/29 11:00
Have Opus Genetics Insiders Been Selling Stock?
Simply Wall St · 10/29 10:11
Weekly Report: what happened at IRD last week (1019-1023)?
Weekly Report · 10/26 09:58
Opus Genetics Eyes 2029 Runway as Presbyopia Drop Wins FDA Approval
NASDAQ · 10/25 12:02
Opus Genetics Is Maintained at Buy by Chardan Capital
Dow Jones · 10/22 12:57
Opus Genetics Price Target Maintained With a $16.00/Share by Chardan Capital
Dow Jones · 10/22 12:57
Opus Genetics Announces Transition of Chief Scientific Officer
TipRanks · 10/21 21:53
Opus Genetics announces FDA clearance of OPGx-RDH12 IND application
TipRanks · 10/21 11:06
FDA Clears Opus Genetics’ IND Application For Opgx-RDH12, Investigational Gene Therapy For Treatment Of RDH12-Associated Leber Congenital Amaurosis
Benzinga · 10/21 11:03
Analysts Are Bullish on These Healthcare Stocks: Opus Genetics (IRD), HUTCHMED (HCM)
TipRanks · 10/19 19:40
Opus Genetics: Advancing BEST1 Program and Targeting Strategy Supports Buy Rating and Unchanged $17 Price Target
TipRanks · 10/19 16:35
Analysts Are Bullish on Top Healthcare Stocks: Opus Genetics (IRD), United Therapeutics (UTHR)
TipRanks · 10/19 11:50
Weekly Report: what happened at IRD last week (1012-1016)?
Weekly Report · 10/19 09:58
Opus Genetics Price Target Maintained With a $17.00/Share by Citizens
Dow Jones · 10/16 20:35
Viatris, Opus granted FDA label expansion for Ryzumvi in presbyopia
Seeking Alpha · 10/16 16:55
Opus Genetics reports FDA approval of phentolamine ophthalmic solution 0.75%
TipRanks · 10/16 16:05
More
Webull provides a variety of real-time IRD stock news. You can receive the latest news about Opus Genetics through multiple platforms. This information may help you make smarter investment decisions.
About IRD
Opus Genetics, Inc. is a clinical-stage ophthalmic biotechnology company. The Company is engaged in developing gene therapies for the treatment of inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. The Company’s pipeline includes adeno-associated virus (AAV)-based investigational gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. Its pipeline also includes OPGx-BEST1 investigational gene therapy, designed to address mutations in the BEST1 gene, which is associated with retinal degeneration. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist being investigated to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 being investigated to slow the progression of non-proliferative diabetic retinopathy.